EyeBio Alternatives & Competitors
12 companies similar to EyeBio — Developing a new generation of therapies to protect, restore, and improve vision
Companies similar to EyeBio
REGENXBIO
Seeking to improve lives through the curative potential of gene therapy.
Rockville, United States
Paris, France
Complement Therapeutics
Developing the next generation of complement medicines
Germany
Vantage Biosciences
Transforming diabetic eye disease with an oral treatment
London, United Kingdom
Rival Readout
Competing with EyeBio? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Calluna Pharma
Developing first-in-class therapies designed to defeat chronic inflammation and fibrosis a...
Oslo, Norway
VIAN Therapeutics
Protecting sight with a simple eye drop.
San Francisco, United Sta...
Inotek Pharmaceuticals
Innovative molecules addressing critical eye diseases for millions.
Japan
Hemera Biosciences LLC
Developing HMR59, an intravitreal gene therapy, to preserve vision in eyes with dry age-re...
Waltham, United States
4D Molecular Therapeutics
Powering the Future of Genetic Medicines
Emeryville, United States
Adverum Biotechnologies
We are on a global mission to establish gene therapy as a new standard of care for the lea...
Redwood City, United Stat...
Ray Therapeutics, Inc.
Optogenetic Gene Therapy Company
Berkeley, United States
About EyeBio
EyeBio, founded in 2021, is an innovative biotechnology company based in the United Kingdom, specializing in ophthalmology. The company's driving mission, encapsulated in its slogan—"Developing a new generation of therapies to protect, restore, and improve vision"—focuses on addressing the unmet needs of patients with...
Research and Development, Therapeutic Modalities, Clinical Trials, Patient Support Programs, Business Development and Licensing, Philanthropy and Medical Outreach
Patients with Retinal Diseases, Healthcare Professionals, Research Scientists, Pharmaceutical Distributors, Investors, Healthcare Institutions
Ophthalmology, Biopharmaceuticals, Vision Therapy, Eye Diseases, Age-related Macular Degeneration, Anti-vascular Endothelial Growth Factor, Sight Restoration, Eye Disorder Prevention, Vision Improvement, Regenerative Medicine, Drug Development, Therapeutics, Vision Protection, Sight-threatening Conditions
B2B
Licensing, Product Sales
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around EyeBio: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at EyeBio on 28 Jan 2026. The 12 companies listed here were last checked between 26 Jul 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
